EU Biotech Act I focuses on important measures

The first part of the EU Biotech Act, published by the European Commission on December 16, brings together numerous measures to improve the framework conditions for research and development in medical biotechnology in Europe, such as the approval of clinical trials, the expansion of bioproduction, and access to capital. Regulations for feed and food and genetically modified microorganisms are also to be adapted in order to strengthen the highly innovative biotechnology industry in Europe in international competition. The biotechnology industry association BIO Deutschland e. V. welcomes the package of measures and is now pushing for its rapid implementation.